

FOR IMMEDIATE RELEASE

September 2, 2022

CONTACT:

Press@FLCCC.net

The Latest Peer-Reviewed Research: Ivermectin Reduces Mortality Rate from COVID-19 by 92% With Regular Use

A strictly controlled study of over 88,000 people showed a direct relationship between the dose of ivermectin and the level of protection against the SARS-CoV-2 virus

WASHINGTON, D.C. – An international team of physicians and scientists recently completed the second phase of one of the largest controlled studies on the efficacy of ivermectin to prevent outcomes related to COVID-19 infection. The study, published this week in the [Cureus Journal of Medical Science](#), showed that participants taking regular prophylactic doses of ivermectin had lower rates of infections, hospitalizations, and deaths than those not taking ivermectin regularly. The study also demonstrated a direct relationship between the dose of ivermectin and the level of protection the drug provides. Test subjects that took higher doses of ivermectin for two consecutive days per week for at least six weeks had a 92% reduction in death from COVID-19, according to the study results.

“We showed a dose-response effect, that is, the more you used, the more protection you had, which reinforces our previous conclusions regarding ivermectin efficacy,” said Flavio Cadegiani, M.D., co-author of the study, Founder and CEO, Corpometria Institute, Brazil and member of the Front Line COVID-19 Critical Care Alliance (FLCCC). “We used a large sample of almost 90,000 people in strictly controlled conditions and let the data lead us. The results are hard to refute.”

The study was conducted in the Brazilian city of Itajaí between July 2020 and December 2020 as part of a citywide program to distribute ivermectin as a prophylaxis against the SARS-CoV-2 virus.

“We are very proud of Dr. Cadegiani and his colleagues for the work they did on this study,” said Paul E. Marik, M.D., FCCM, FCCP, founding member of the FLCCC and former Chief, Pulmonary and Critical Care Medicine at Eastern Virginia Medical School.

“The design and administration of this study resulted in a large amount of reliable data that shows, once again, there is no doubt that ivermectin is highly effective as a safe prophylaxis and treatment for COVID-19.”

The published research can be found in the latest edition of the Cureus Journal of Medical Science: https://www.cureus.com/articles/111851-regular-use-of-ivermectin-as-prophylaxis-for-covid-19-led-up-to-a-92-reduction-in-covid-19-mortality-rate-in-a-dose-response-manner-results-of-a-prospective-observational-study-of-a-strictly-controlled-population-of-88012-subjects?email_share=true&expedited_modal=true

About the Front Line COVID-19 Critical Care Alliance

The FLCCC Alliance was organized in March 2020 by a group of highly published, world renowned critical care physicians and scholars with the academic support of allied physicians from around the world. FLCCC’s goal is to research and develop lifesaving protocols for the prevention and treatment of COVID-19 in all stages of illness including long COVID and post-vaccine syndrome. For more information: